Hepion pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Hepion pharmaceuticals Contact Number

Contact Us – Hepion Pharmaceuticals

6 hours ago Hepionpharma.com Show details

(732) 902-4000399 Thornall Street, 1st Floor Edison, NJ 08837 Phone: (732) 902-4000 Fax: (732) 902-4100 [email protected]

Category: Contact SupportShow more

Hepion Pharmaceuticals

5 hours ago Hepionpharma.com Show details

Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular

Category: Contact NumberShow more

Hepion Pharmaceuticals Crunchbase Company Profile & …

5 hours ago Crunchbase.com Show details

(732) 902-4000Contact Email [email protected] Phone Number (732) 902-4000. Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). Its drug candidate, CRV431, reduces liver

Founded: 2013

Category: Contact NumberShow more

About Hepion – Hepion Pharmaceuticals

1 hours ago Hepionpharma.com Show details

Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma …

Category: Contact NumberShow more

Hepion Pharmaceuticals LinkedIn

Just Now Linkedin.com Show details

Hepion Pharmaceuticals Biotechnology Research Edison, New Jersey 948 followers Hepion Pharmaceuticals, Inc. is not affiliated in any way with Wire™ or …

Employees: 17
Location: Edison, 08837, NEW JERSEY

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces FDA Clearance of IND

2 hours ago Biospace.com Show details

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Category: Contact NumberShow more

Form 8K Hepion Pharmaceuticals, For: Jan 09

4 hours ago Streetinsider.com Show details

About Hepion Pharmaceuticals . please contact: Stephen Kilmer. Hepion Pharmaceuticals Investor Relations Information on the Total Number of Voting Rights and Shares of Axway Software Share

Category: Contact NumberShow more

Hepion Pharmaceuticals, Inc (HEPA): $HEPA: CRV431 now

2 hours ago Investorshub.advfn.com Show details

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Category: Contact NumberShow more

Pipeline – Hepion Pharmaceuticals

4 hours ago Hepionpharma.com Show details

Hit enter to search or ESC to close. Close Search. Menu

Category: Contact NumberShow more

All Endpoints Met in Hepion Pharmaceuticals’ DrugDrug

5 hours ago Globenewswire.com Show details

All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431. EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical

Category: Contact NumberShow more

Hepion Pharmaceuticals Receives FDA Fast Track Designation

8 hours ago Biospace.com Show details

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Category: Contact NumberShow more

Newsroom – Hepion Pharmaceuticals

4 hours ago Hepionpharma.com Show details

Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century. Modern biotechnology is a young industry. But in just a few decades, the entrepreneurs, scientists, researchers and investors working in this field have firmly established themselves at the forefront of…. Hepion. May 1, 2017.

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces FDA Clearance of IND

2 hours ago Finance.yahoo.com Show details

EDISON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven

1. Author: Hepion Pharmaceuticals, Inc.

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces USAN Selection of

3 hours ago Finance.yahoo.com Show details

EDISON, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven

Category: Contact NumberShow more

Additional Data from Hepion Pharmaceuticals’ Phase 2a

2 hours ago Globenewswire.com Show details

About Hepion Pharmaceuticals . The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. There are a number of factors

Category: Contact NumberShow more

Hepion Pharmaceuticals Receives FDA Fast Track Designation

Just Now Benzinga.com Show details

Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces Poster Details for the

5 hours ago Globenewswire.com Show details

About Hepion Pharmaceuticals . The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. There are a number of factors

1. Author: Hepion Pharmaceuticals, Inc.

Category: Contact NumberShow more

Hepion Pharmaceuticals to Participate in the H.C.

7 hours ago Globenewswire.com Show details

About Hepion Pharmaceuticals . The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. There are a number of factors

Category: Contact NumberShow more

Current Report Filing (8k)

4 hours ago Ih.advfn.com Show details

On December 21, 2021, Hepion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has accepted its investigational new drug (“IND”) application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (“HCC”). A copy of the

Category: Contact NumberShow more

Hepion Pharmaceuticals AMBITION trial shows positive

1 hours ago Edisongroup.com Show details

Hepion ended Q121 with $115.3m in net cash ($115.5m gross cash offset by $0.2m debt). On 16 February 2021, Hepion, conducted a public offering of 44,200,000 shares of Hepion common stock at a price of $2.00 per share. This resulted in net proceeds of approximately $82.1m, after deducting underwriting discount, commissions and offering …

Category: Contact NumberShow more

Hepion Pharmaceuticals, Inc. (HEPA) Company Profile

4 hours ago Finance.yahoo.com Show details

See the company profile for Hepion Pharmaceuticals, Inc. (HEPA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives

Category: Contact NumberShow more

Hepion Pharmaceuticals Completes Final Patient Recruitment

2 hours ago Finance.yahoo.com Show details

EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces Adjournment of Annual

8 hours ago Ir.contravir.com Show details

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting

7 hours ago Finance.yahoo.com Show details

800-749-9052North American Toll Free Phone: 1-800-749-9052. Email: [email protected] Call Collect Outside North America: 416-867-2272. About Hepion Pharmaceuticals . Hepion’s lead drug

Category: Contact NumberShow more

ContraVir Pharmaceuticals Announces Name Change to Hepion

2 hours ago Globenewswire.com Show details

About Hepion Pharmaceuticals. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. please contact

Category: Contact NumberShow more

Hepion Pharma reports anticancer activity of CRV431 in a

2 hours ago Seekingalpha.com Show details

Hepion Pharmaceuticals (NASDAQ: HEPA) announces the results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer

Category: Contact NumberShow more

Current Report Filing (8k)

4 hours ago Ih.advfn.com Show details

Washington, DC 20549. FORM 8-K. CURRENT REPORT. Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934. Date of Report (Date of earliest event reported): January 9, 2022. Hepion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware. 001-36856.

Category: Contact NumberShow more

Hepion Pharmaceuticals First data on liver enzymes

6 hours ago Edisongroup.com Show details

Hepion has announced interim results from its ongoing Phase IIa study of CRV431 in non-alcoholic steatohepatitis (NASH). The preliminary results are from the low-dose arm of the study (75mg, n=12) and showed a 18.4% decline in alanine aminotransferase (ALT) and a 12.1% decline in aspartate aminotransferase (AST) liver biomarkers after 28 days. Although these …

Category: Contact NumberShow more

All Endpoints Met in Hepion Pharmaceuticals' DrugDrug

8 hours ago Benzinga.com Show details

Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission.

Category: Contact NumberShow more

Hepion Pharmaceuticals Inc (HEPA) Up 2.03% in Premarket

2 hours ago Investorsobserver.com Show details

Hepion Pharmaceuticals Inc has a Long-Term Technical rank of 8. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 92% of the market scoring higher. In the Biotechnology industry which is number 136 by this metric, HEPA ranks better than 24% of stocks. Important Dates for Investors in

Category: Contact NumberShow more

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

7 hours ago Ih.advfn.com Show details

HEPION PHARMACEUTICALS, INC. Up to $7,000,000 of Shares . Common Stock . To date, in vivo studies in a number of animal models of fibrosis and HCC have repeatedly and consistently demonstrated that CRV431 reduces fibrosis scores and overall liver tumor burden. Other models including in vitro and ex vivo (human precision cut liver slices

Category: Contact NumberShow more

Hepion Pharmaceuticals, Inc. Announces Proposed Public

1 hours ago Apnews.com Show details

Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission.

Category: Contact NumberShow more

ContraVir Pharmaceuticals Announces Name Change to Hepion

3 hours ago Ir.contravir.com Show details

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2018 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Category: Contact NumberShow more

Hepion Pharmaceuticals, Inc. Announces Closing of Public

2 hours ago Apnews.com Show details

EDISON, NJ / ACCESSWIRE / February 18, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), today announced the closing of its previously announced public offering of 44,200,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $88,400,000, before deducting underwriting discounts and offering expenses.

Category: Contact NumberShow more

Will Hepion Pharmaceuticals Inc (HEPA) Trail the Rest of

2 hours ago Investorsobserver.com Show details

Hepion Pharmaceuticals Inc is near the bottom in its sector according to InvestorsObserver. HEPA gets an overall rating of 5. That means it scores higher than 5% of stocks. Hepion Pharmaceuticals Inc gets a 4 rank in the Healthcare sector. Healthcare is number 6 out of 11 sectors.

Category: Contact NumberShow more

HEPA Stock Hepion Pharmaceuticals, Inc. SEC Filings

Just Now Sec.report Show details

Ticker: HEPA. documents---0.0010058879852295. Hepion Pharmaceuticals, Inc. is incorporated in the state of Delaware. Hepion Pharmaceuticals, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st.

Category: Contact NumberShow more

Hepion Pharmaceuticals Receives FDA Fast Track Designation

1 hours ago Morningstar.com Show details

About Hepion Pharmaceuticals . The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. There are a number of factors

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces USAN Selection of

3 hours ago Morningstar.com Show details

About Hepion Pharmaceuticals . There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. please contact

Category: Contact NumberShow more

Hepion Pharmaceuticals Inc (HEPA) is higher by 4.88%

2 hours ago Investorsobserver.com Show details

Hepion Pharmaceuticals Inc has a Long-Term Technical rank of 24. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 76% of the market scoring higher. In the Biotechnology industry which is number 141 by this metric, HEPA ranks better than 50% of stocks. Important Dates for Investors in

Category: Contact NumberShow more

Hepion Pharmaceuticals VentureRadar

3 hours ago Ventureradar.com Show details

Listed Company. "Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces USAN Selection of

Just Now Biospace.com Show details

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Category: Contact NumberShow more

SEC Filing Hepion Pharmaceuticals, Inc.

8 hours ago Ir.contravir.com Show details

ContraVir Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware . 000-55020 . 46-2783806 (State or other jurisdiction (Commission . IRS Employer. of incorporation or organization) File Number) Identification No.) 399 Thornall Street, First Floor. Edison, NJ 08837 (Address of principal executive offices)

Category: Contact NumberShow more

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional

3 hours ago Biospace.com Show details

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Category: Contact NumberShow more

HEPA News Today (Hepion Pharmaceuticals) MarketBeat

1 hours ago Marketbeat.com Show details

Hepion Pharmaceuticals to Present on CRV431 and AI-POWR at NASH-TAG 2021 ca.finance.yahoo.com - March 11 at 4:12 PM: Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals to Present on CRV431 and AI-POW at NASH-TAG 2021 finanznachrichten.de - March 11 at 7:51 AM: Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at …

Category: Contact NumberShow more

Hepion Pharmaceuticals Announces USAN Selection of

Just Now Marketwatch.com Show details

431-2022-01Press Release Hepion Pharmaceuticals Announces USAN Selection of "Rencofilstat" as Nonproprietary Name for CRV431 Published: Jan. 6, 2022 at 4:15 p.m. ET

Category: Contact NumberShow more

See why the forecast is trending for $HEPA – The Wall

1 hours ago Wallstreetfacts.com Show details

The 52-week high for Hepion Pharmaceuticals Inc is 3.18 and the low is 1.12. Now we would like to inform you with the number of outstanding shares. You are able to use shares that are outstanding to calculate, as well as analyze the market capitalization and total value of a corporation.

Category: Contact NumberShow more

Should You Hold Hepion Pharmaceuticals Inc (HEPA) Stock

Just Now Investorsobserver.com Show details

Hepion Pharmaceuticals Inc has a Long-Term Technical rank of 27. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 73% of the market scoring higher. In the Biotechnology industry which is number 141 by this metric, HEPA ranks better than 63% of stocks. Important Dates for Investors in

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What does hepion pharmaceuticals do?

Learn more >> Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).

What is the lead drug candidate for hepion pharmaceuticals?

About Hepion Pharmaceuticals, Inc. The Company’s lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes.

What are forward-looking statements about hepion pharmaceuticals?

These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.

What is hepion’s new name for the drug?

Going forward, Hepion will use the name “rencofilstat” in upcoming publications and public statements, at conferences and other forums, as the Company continues to advance the drug’s clinical development.

Popular Brands

Hms
Holmen
Hyatt